Cancer Stem Cell Markers in Rhabdomyosarcoma in Children

Area of Science:

• Pediatric Oncology
• Cancer Stem Cell Biology
• Rhabdomyosarcoma Research

Background:

• Rhabdomyosarcoma (RMS) is a common pediatric soft tissue sarcoma.
• Cancer stem cells (CSCs) are implicated in tumor initiation, progression, and treatment resistance.
• Identifying CSC markers in RMS is crucial for understanding disease mechanisms and developing targeted therapies.

Purpose of the Study:

• To investigate the expression of CSC markers CD24, CD44, CD133, and ALDH1A1 in pediatric RMS.
• To determine the prognostic value of these CSC markers in children diagnosed with RMS.

Main Methods:

• Archival tissue specimens from 49 pediatric RMS patients were analyzed.
• Immunohistochemistry (IHC) was employed to assess the expression levels of CD24, CD44, CD133, and ALDH1A1.
• Expression was quantified using a semiquantitative IRS scale and correlated with clinical-pathological parameters.

Main Results:

• High expression rates of CD24 (83.7%), CD44 (55.1%), CD133 (81.6%), and ALDH1A1 (100%) were observed in RMS tissues.
• Expression of all assessed CSC markers was significantly higher in RMS patients compared to controls.
• No significant correlation was found between CSC marker expression and established prognostic factors or survival rates in RMS.

Conclusions:

• The study confirms the presence of CD24, CD44, CD133, and ALDH1A1 in pediatric rhabdomyosarcoma.
• The assessed CSC markers do not appear to hold prognostic relevance for survival in pediatric RMS patients.
• Further research is warranted to elucidate the role of these CSC markers in RMS development and progression.